Literature DB >> 17141798

The assembly of single domain antibodies into bispecific decavalent molecules.

Emily Stone1, Tomoko Hirama, Jamshid Tanha, Hong Tong-Sevinc, Shenghua Li, C Roger MacKenzie, Jianbing Zhang.   

Abstract

Bispecific antibodies present unique opportunities in terms of new applications for engineered antibodies. However, designing ideal bispecific antibodies remains a challenge. Here we describe a novel bispecific antibody model in which five single domain antibodies (sdAbs) are fused via a linker sequence to the N-terminus of the verotoxin B (VTB) subunit, a pentamerization domain, and five sdAbs are fused via a linker sequence to the VTB C-terminus. Fifteen such decavalent bispecific molecules, termed decabodies, were constructed and characterized for the purpose of identifying an optimal decabody design. One of the fifteen molecules existed in a non-aggregated decavalent form. In conjunction with the isolation of sdAbs with the desired specificities from non-immune phage display libraries, the decabody strategy provides a means of generating high avidity bispecific antibody reagents, with good physical properties, relatively quickly.

Mesh:

Substances:

Year:  2006        PMID: 17141798     DOI: 10.1016/j.jim.2006.10.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  An Ultrasensitive Bioluminescent Enzyme Immunoassay Based on Nanobody/Nanoluciferase Heptamer Fusion for the Detection of Tetrabromobisphenol A in Sediment.

Authors:  Zhenfeng Li; Yi Wang; Natalia Vasylieva; Debin Wan; Zihan Yin; Jiexian Dong; Bruce D Hammock
Journal:  Anal Chem       Date:  2020-07-07       Impact factor: 6.986

2.  Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.

Authors:  Fangling Ji; Jun Ren; Cécile Vincke; Lingyun Jia; Serge Muyldermans
Journal:  Methods Mol Biol       Date:  2022

3.  Analysis of the relationship between end-to-end distance and activity of single-chain antibody against colorectal carcinoma.

Authors:  Jianhua Zhang; Shanhong Liu; Zhigang Shang; Li Shi; Jun Yun
Journal:  Theor Biol Med Model       Date:  2012-08-22       Impact factor: 2.432

Review 4.  Biotechnological applications of recombinant single-domain antibody fragments.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2011-06-09       Impact factor: 5.328

5.  Multivalent anchoring and oriented display of single-domain antibodies on cellulose.

Authors:  Greg Hussack; Yan Luo; Linda Veldhuis; J Christopher Hall; Jamshid Tanha; Roger Mackenzie
Journal:  Sensors (Basel)       Date:  2009-07-07       Impact factor: 3.576

6.  Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials.

Authors:  Laura Sánchez-García; Eric Voltà-Durán; Eloi Parladé; Elisa Mazzega; Alejandro Sánchez-Chardi; Naroa Serna; Hèctor López-Laguna; Mara Mitstorfer; Ugutz Unzueta; Esther Vázquez; Antonio Villaverde; Ario de Marco
Journal:  ACS Appl Mater Interfaces       Date:  2021-06-15       Impact factor: 10.383

7.  Shiga-like toxin B subunit of Escherichia coli as scaffold for high-avidity display of anti-immunocomplex peptides.

Authors:  Gabriel Lassabe; Martín Rossotti; Andrés González-Techera; Gualberto González-Sapienza
Journal:  Anal Chem       Date:  2014-05-21       Impact factor: 6.986

8.  Linking Single Domain Antibodies that Recognize Different Epitopes on the Same Target.

Authors:  Richard H Glaven; George P Anderson; Dan Zabetakis; Jinny L Liu; Nina C Long; Ellen R Goldman
Journal:  Biosensors (Basel)       Date:  2012-02-01

Review 9.  Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics.

Authors:  Eugene M Obeng; Christian K O Dzuvor; Michael K Danquah
Journal:  Nano Today       Date:  2021-11-23       Impact factor: 20.722

10.  Heptameric targeting ligands against EGFR and HER2 with high stability and avidity.

Authors:  Dongwook Kim; Yitang Yan; C Alexander Valencia; Rihe Liu
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.